Emergent BioSolutions (EBS) Net Cash Flow (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Net Cash Flow of -$47.6 million for Q1 2026, down 199.37% year-over-year from $47.9 million in Q1 2025, and down 18.7% quarter-over-quarter from -$40.1 million in Q4 2025.
Emergent BioSolutions (EBS) Net Cash Flow (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$47.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 199.37% year-over-year to -$47.6 million; the TTM figure through Mar 2026 stood at $7.9 million (down 89.4% YoY), while the FY2025 annual figure was $103.4 million, up 1795.08% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$47.6 million, down from -$40.1 million in the prior quarter.
- The five-year high for Net Cash Flow was $400.5 million in Q4 2022, with the low at -$343.6 million in Q2 2023.
- The 5-year median for Net Cash Flow is -$32.7 million (2024), against an average of -$24.4 million.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow plunged 338.27% in 2023, then surged 4594.74% in 2024.
- Emergent BioSolutions' Net Cash Flow stood at $400.5 million in 2022, then sank by 93.66% to $25.4 million in 2023, then slumped by 300.0% to -$50.8 million in 2024, then grew by 21.06% to -$40.1 million in 2025, then declined by 18.7% to -$47.6 million in 2026.
- Business Quant data shows EBS's Net Cash Flow at -$47.6 million in Q1 2026, -$40.1 million in Q4 2025, and -$21.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -20.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.60 Mn |
| Jun 30, 2026 | -20.60 Mn |
| Mar 31, 2026 | -47.60 Mn |
| Mar 31, 2026 | -47.60 Mn |
| Dec 31, 2025 | -40.10 Mn |
| Dec 31, 2025 | -40.10 Mn |
| Sep 30, 2025 | -21.60 Mn |
| Sep 30, 2025 | -21.60 Mn |
| Jun 30, 2025 | 117.20 Mn |
| Jun 30, 2025 | 117.20 Mn |
| Mar 31, 2025 | 47.90 Mn |
| Mar 31, 2025 | 47.90 Mn |
| Dec 31, 2024 | -50.80 Mn |
| Dec 31, 2024 | -50.80 Mn |
| Sep 30, 2024 | 85.40 Mn |
| Sep 30, 2024 | 85.40 Mn |
| Jun 30, 2024 | -8.00 Mn |
| Jun 30, 2024 | -8.00 Mn |
| Mar 31, 2024 | -32.70 Mn |
| Mar 31, 2024 | -32.70 Mn |